Inflammation-driven changes in bone marrow: An early indicator of leukemia?

What if we could stop blood cancers before they even start? New research reveals ¹ that chronic inflammation dramatically reshapes the bone marrow environment years before leukemia emerges, potentially offering a window for early intervention.

The Hidden Life of the Bone Marrow

Every second, your bone marrow produces millions of new blood and immune cells through delicate cooperation between blood stem cells and supportive stromal cells. Over time, aging, inflammation, or genetic mutations can disrupt this partnership, allowing mutated stem cells to silently expand.

This leads to a condition called clonal hematopoiesis, or CHIP, which affects roughly 10–20% of adults over 60 years old. Despite the lack of symptoms, the condition increases blood cancer risk tenfold and doubles the risk of cardiovascular disease. In some cases, it can progress to myelodysplastic syndrome, where bone marrow fails to produce healthy blood cells, and up to 30% of these advance to acute myeloid leukemia—an aggressive and often fatal blood cancer.

Uncovering the Culprit: Inflammation

Researchers conducted an in-depth molecular analysis of human bone marrow samples from healthy donors, people with CHIP, and patients with myelodysplastic syndrome (leukaemia). Using advanced techniques including single-cell sequencing and biopsy imaging, they built a high-resolution map of the bone marrow environment across these different stages.

The results revealed a striking cellular transformation beginning well before clinical disease appears. Researchers identified inflammatory stromal cells instead of normal stem-cell-supporting cells. Unlike healthy stromal cells, these inflammatory cells release signaling molecules that attract and activate certain immune cells (T cells). In turn, these T cells amplify the inflammatory signal, creating a self-reinforcing loop that sustains chronic inflammation, suppresses healthy blood formation, and promotes abnormal blood vessel development.

Surprisingly, the mutated blood cells do not directly drive inflammation. Instead, the inflammatory network in the surrounding microenvironment becomes dominant, replacing much of the bone marrow’s regenerative structure. As diseased stem cells also fail to trigger production of important signaling molecules, this could explain why bone marrow function deteriorates.

This discovery indicates inflammation has a central force in early blood disease stages and establishes the bone marrow microenvironment as a critical therapeutic target. Based on these findings, anti-inflammatory treatments may help preserve bone marrow function in older adults with CHIP. In addition, the distinct molecular signatures of these inflammatory cells may serve as biomarkers to identify at-risk individuals long before clinical symptoms emerge, possibly preventing progression to leukemia.

What I find particularly interesting about the research is that it shows yet another example of how deadly chronic infammation can be. I would not be surprised if the incidence of this disease were to increase in the next years, as we are most living under chronic stress conditions, which is one of the biggest contributors to chronic inflammation. To me, this is more of a health issue, it is a social issue and to get rid of it, we need much more than antiinflammatory drugs.